Broadening the repertoire of melanoma-associated T-cell epitopes

Thomas Mørch Frøsig; Rikke Lyngaa; Özcan Met; Stine Kiaer Larsen; Marco Donia; Inge Marie Svane; Per Thor Straten; Sine Reker Hadrup

doi:10.1007/s00262-015-1664-x

Broadening the repertoire of melanoma-associated T-cell epitopes

Thomas Mørch Frøsig, Rikke Lyngaa, Özcan Met, Stine Kiaer Larsen, Marco Donia, Inge Marie Svane, Per Thor Straten, Sine Reker Hadrup

Institut for Klinisk Medicin

8 Citationer (Scopus)

Abstract

Immune therapy has provided a significant breakthrough in the treatment of metastatic melanoma. Despite the remarkable clinical efficacy and established involvement of effector CD8 T cells, the knowledge of the exact peptide-MHC complexes recognized by T cells on the tumor cell surface is limited. Many melanoma-associated T-cell epitopes have been described, but this knowledge remains largely restricted to HLA-A2, and we lack understanding of the T-cell recognition in the context of other HLA molecules. We selected six melanoma-associated antigens (MAGE-A3, NY-ESO-1, gp100, Mart1, tyrosinase and TRP-2) that are frequently recognized in patients with the aim of identifying novel T-cell epitopes restricted to HLA-A1, -A3, -A11 and -B7. Using in silico prediction and in vitro confirmation, we identified 127 MHC ligands and analyzed the T-cell responses against these ligands via the MHC multimer-based enrichment of peripheral blood from 39 melanoma patients and 10 healthy donors. To dissect the T-cell reactivity against this large peptide library, we used combinatorial-encoded MHC multimers and observed the T-cell responses against 17 different peptide-MHC complexes in the patient group and four in the healthy donor group. We confirmed the processing and presentation of HLA-A3-restricted T-cell epitopes from tyrosinase (TQYESGSMDK) and gp100 (LIYRRRLMK) and an HLA-A11-restricted T-cell epitope from gp100 (AVGATKVPR) via the cytolytic T-cell recognition of melanoma cell lines and/or K562 cells expressing the appropriate antigen and HLA molecule. We further found T-cell reactivity against two of the identified sequences among tumor-infiltrating lymphocytes from melanoma patients, suggesting a potential clinical relevance of these sequences.

Originalsprog	Engelsk
Tidsskrift	Cancer immunology, immunotherapy : CII
Vol/bind	64
Udgave nummer	5
Sider (fra-til)	609-20
Antal sider	12
ISSN	0340-7004
DOI	https://doi.org/10.1007/s00262-015-1664-x
Status	Udgivet - 21 apr. 2015

Adgang til dokumentet

10.1007/s00262-015-1664-xLicens: CC BY

Citationsformater

@article{080a1d4a149e4d47b66d8fa6311fd924,

title = "Broadening the repertoire of melanoma-associated T-cell epitopes",

abstract = "Immune therapy has provided a significant breakthrough in the treatment of metastatic melanoma. Despite the remarkable clinical efficacy and established involvement of effector CD8 T cells, the knowledge of the exact peptide-MHC complexes recognized by T cells on the tumor cell surface is limited. Many melanoma-associated T-cell epitopes have been described, but this knowledge remains largely restricted to HLA-A2, and we lack understanding of the T-cell recognition in the context of other HLA molecules. We selected six melanoma-associated antigens (MAGE-A3, NY-ESO-1, gp100, Mart1, tyrosinase and TRP-2) that are frequently recognized in patients with the aim of identifying novel T-cell epitopes restricted to HLA-A1, -A3, -A11 and -B7. Using in silico prediction and in vitro confirmation, we identified 127 MHC ligands and analyzed the T-cell responses against these ligands via the MHC multimer-based enrichment of peripheral blood from 39 melanoma patients and 10 healthy donors. To dissect the T-cell reactivity against this large peptide library, we used combinatorial-encoded MHC multimers and observed the T-cell responses against 17 different peptide-MHC complexes in the patient group and four in the healthy donor group. We confirmed the processing and presentation of HLA-A3-restricted T-cell epitopes from tyrosinase (TQYESGSMDK) and gp100 (LIYRRRLMK) and an HLA-A11-restricted T-cell epitope from gp100 (AVGATKVPR) via the cytolytic T-cell recognition of melanoma cell lines and/or K562 cells expressing the appropriate antigen and HLA molecule. We further found T-cell reactivity against two of the identified sequences among tumor-infiltrating lymphocytes from melanoma patients, suggesting a potential clinical relevance of these sequences.",

keywords = "Cell Line, Tumor, Epitopes, T-Lymphocyte, HLA Antigens, HLA-A1 Antigen, HLA-A11 Antigen, HLA-A3 Antigen, HLA-B7 Antigen, Humans, Immunotherapy, Adoptive, Leukocytes, Mononuclear, Lymphocytes, Tumor-Infiltrating, Melanoma, Melanoma-Specific Antigens, Peptide Mapping, T-Lymphocytes, Cytotoxic",

author = "Fr{\o}sig, {Thomas M{\o}rch} and Rikke Lyngaa and {\"O}zcan Met and Larsen, {Stine Kiaer} and Marco Donia and Svane, {Inge Marie} and {Thor Straten}, Per and Hadrup, {Sine Reker}",

year = "2015",

month = apr,

day = "21",

doi = "10.1007/s00262-015-1664-x",

language = "English",

volume = "64",

pages = "609--20",

journal = "Cancer Immunology, Immunotherapy",

issn = "0340-7004",

publisher = "Springer",

number = "5",

}

TY - JOUR

T1 - Broadening the repertoire of melanoma-associated T-cell epitopes

AU - Frøsig, Thomas Mørch

AU - Lyngaa, Rikke

AU - Met, Özcan

AU - Larsen, Stine Kiaer

AU - Donia, Marco

AU - Svane, Inge Marie

AU - Thor Straten, Per

AU - Hadrup, Sine Reker

PY - 2015/4/21

Y1 - 2015/4/21

N2 - Immune therapy has provided a significant breakthrough in the treatment of metastatic melanoma. Despite the remarkable clinical efficacy and established involvement of effector CD8 T cells, the knowledge of the exact peptide-MHC complexes recognized by T cells on the tumor cell surface is limited. Many melanoma-associated T-cell epitopes have been described, but this knowledge remains largely restricted to HLA-A2, and we lack understanding of the T-cell recognition in the context of other HLA molecules. We selected six melanoma-associated antigens (MAGE-A3, NY-ESO-1, gp100, Mart1, tyrosinase and TRP-2) that are frequently recognized in patients with the aim of identifying novel T-cell epitopes restricted to HLA-A1, -A3, -A11 and -B7. Using in silico prediction and in vitro confirmation, we identified 127 MHC ligands and analyzed the T-cell responses against these ligands via the MHC multimer-based enrichment of peripheral blood from 39 melanoma patients and 10 healthy donors. To dissect the T-cell reactivity against this large peptide library, we used combinatorial-encoded MHC multimers and observed the T-cell responses against 17 different peptide-MHC complexes in the patient group and four in the healthy donor group. We confirmed the processing and presentation of HLA-A3-restricted T-cell epitopes from tyrosinase (TQYESGSMDK) and gp100 (LIYRRRLMK) and an HLA-A11-restricted T-cell epitope from gp100 (AVGATKVPR) via the cytolytic T-cell recognition of melanoma cell lines and/or K562 cells expressing the appropriate antigen and HLA molecule. We further found T-cell reactivity against two of the identified sequences among tumor-infiltrating lymphocytes from melanoma patients, suggesting a potential clinical relevance of these sequences.

AB - Immune therapy has provided a significant breakthrough in the treatment of metastatic melanoma. Despite the remarkable clinical efficacy and established involvement of effector CD8 T cells, the knowledge of the exact peptide-MHC complexes recognized by T cells on the tumor cell surface is limited. Many melanoma-associated T-cell epitopes have been described, but this knowledge remains largely restricted to HLA-A2, and we lack understanding of the T-cell recognition in the context of other HLA molecules. We selected six melanoma-associated antigens (MAGE-A3, NY-ESO-1, gp100, Mart1, tyrosinase and TRP-2) that are frequently recognized in patients with the aim of identifying novel T-cell epitopes restricted to HLA-A1, -A3, -A11 and -B7. Using in silico prediction and in vitro confirmation, we identified 127 MHC ligands and analyzed the T-cell responses against these ligands via the MHC multimer-based enrichment of peripheral blood from 39 melanoma patients and 10 healthy donors. To dissect the T-cell reactivity against this large peptide library, we used combinatorial-encoded MHC multimers and observed the T-cell responses against 17 different peptide-MHC complexes in the patient group and four in the healthy donor group. We confirmed the processing and presentation of HLA-A3-restricted T-cell epitopes from tyrosinase (TQYESGSMDK) and gp100 (LIYRRRLMK) and an HLA-A11-restricted T-cell epitope from gp100 (AVGATKVPR) via the cytolytic T-cell recognition of melanoma cell lines and/or K562 cells expressing the appropriate antigen and HLA molecule. We further found T-cell reactivity against two of the identified sequences among tumor-infiltrating lymphocytes from melanoma patients, suggesting a potential clinical relevance of these sequences.

KW - Cell Line, Tumor

KW - Epitopes, T-Lymphocyte

KW - HLA Antigens

KW - HLA-A1 Antigen

KW - HLA-A11 Antigen

KW - HLA-A3 Antigen

KW - HLA-B7 Antigen

KW - Humans

KW - Immunotherapy, Adoptive

KW - Leukocytes, Mononuclear

KW - Lymphocytes, Tumor-Infiltrating

KW - Melanoma

KW - Melanoma-Specific Antigens

KW - Peptide Mapping

KW - T-Lymphocytes, Cytotoxic

U2 - 10.1007/s00262-015-1664-x

DO - 10.1007/s00262-015-1664-x

M3 - Journal article

C2 - 25854582

SN - 0340-7004

VL - 64

SP - 609

EP - 620

JO - Cancer Immunology, Immunotherapy

JF - Cancer Immunology, Immunotherapy

IS - 5

ER -

Broadening the repertoire of melanoma-associated T-cell epitopes

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater